p53 is necessary for the elimination of neural cells inappropriately differentiated or in response to stimuli. However, the role of p53 in neuronal differentiation is not certain. Here, we showed that nerve growth factor (NGF)-mediated differentiation in PC12 cells is enhanced by overexpression of wild-type p53 but inhibited by mutant p53 or knockdown of endogenous wild-type p53, the latter of which can be rescued by expression of exogenous wild-type p53. Interestingly, p53 knockdown or overexpression of mutant p53 attenuates NGF-mediated activation of TrkA, the high-affinity receptor for NGF and a tyrosine kinase, and activation of the mitogen-activated protein kinase pathway. In addition, p53 knockdown reduces the constitutive levels of TrkA, which renders PC12 cells inert to NGF. And finally, we showed that both constitutive and stimuli-induced expressions of TrkA are regulated by p53 and that induction of TrkA by activated endogenous p53 enhances NGFmediated differentiation. Taken together, our data demonstrate that p53 plays a critical role in NGF-mediated neuronal differentiation in PC12 cells at least in part via regulation of TrkA levels.
Introduction
Nerve growth factor (NGF) 1 has profound effects on the differentiation and survival of a subset of neurons, 2 which is primarily studied in PC12 cells, a model system for neuronal differentiation. 3 Upon exposure to NGF, PC12 cells cease division, extend neurites, and acquire characteristics similar to sympathetic neurons. 2 This is largely mediated through the binding of NGF to TrkA, the high-affinity NGF receptor, which undergoes dimerization and autophosphorylation and then activates two major pathways: the mitogen-activated protein kinase (MAPK) pathway for neurite outgrowth and the PI3K pathway for neural survival. p53 transcription factor regulates a diverse array of target genes that mediate tumor suppression by inducing cell cycle arrest and apoptosis. [4] [5] [6] In the nervous system, p53 is essential for the elimination of inappropriately differentiated neural progenitors and for neuronal apoptosis in response to stimuli. 7, 8 p53 may play a role in neuronal differentiation, but current knowledge is controversial. The first implication comes from the observation that some p53-deficient mice developed exencephalic brains. 9 Later studies showed that p53 expression oscillates in neuronal cells undergoing differentiation 10 and during development. 11 In addition, NGF-mediated neuronal differentiation was showed to be inhibited by a dominant-negative form of p53. 10, 12 Furthermore, several p53 target genes, such as p21 and BTG2, play a role in neuronal differentiation. 4 However, other studies disputed such a role for p53. For example, p53 was found to be necessary for NGF-mediated cell cycle arrest, but not neurite outgrowth 13 and suppression of p53 was found to enhance, rather than attenuate, neuronal differentiation. 14 To further address this, we examined the role of p53 in NGF-mediated neuronal differentiation and provided evidence that p53 plays a critical role in NGF-mediated neuronal differentiation at least in part via regulation of TrkA levels.
Results

Exogenous p53 promotes NGF-mediated neurite outgrowth in PC12 cells
To investigate the role of p53 in NGF-mediated differentiation, we generated PC12 cell lines that inducibly express HAtagged wild-type murine p53. Multiple clones were selected and two representative clones, which express comparable amounts of p53, were chosen for further studies ( Figure 1A ). Listed in Table 1 is a brief summary of cell lines used and/or generated in this study. To verify the activity of HA-p53, the level of p21 was examined and found to be induced ( Figure 1A ). Next, we performed growth rate assay and found that cells failed to proliferate in the presence of p53 ( Figure 1B and C). Since p53 overexpression can lead to either cell cycle arrest or apoptosis, it is necessary to make sure that the level of p53 expressed in these cell lines does not induce apoptosis, which would obliterate the effect of p53 on neuronal differentiation. The number of cells with sub-G1 DNA content directly correlates with the degree of cells undergoing apoptosis. Thus, we performed DNA histogram assay and found that upon p53 induction, PC12-HA-p53-46 cells arrested primarily in G1 ( Figure 1D ). However, PC12-HA-p53-98, which is capable of expressing a higher level of p53 ( Figure 1E ), underwent apoptosis as the percentage of cells with sub-G1 DNA content increased from 1.1 to 8.1% upon induction of p53 ( Figure 1F) .
To test the effect of p53, PC12 cells were uninduced or induced to express p53, followed by NGF treatment for 3 days. The cell morphology was examined by phase-contrast microscopy. We found that NGF treatment was able to induce PC12 cells to undergo differentiation (Figure 1Gc ) whereas overexpression of p53 alone did not (Figure 1Gb ). Interestingly, we observed that upon NGF treatment, PC12 cells with p53 overexpression extended more and longer neurites compared to cells without p53 overexpression (Figure 1Gc-d) . To confirm this, neurite outgrowth was quantified ( Figure 1H ). Cells with neurites are defined as ones that possess at least one neurite of greater than two-body length and at least 500 cells were assayed in each group. We found that the percentage of cells with neurites longer than two-body length was highly increased by p53, ranging from 100 to 130% ( Figure 1H ). Next, we analyzed the expression of p21 and GAP-43. p21 plays a role in NGF-mediated differentiation by inducing cell cycle arrest in G1 15 whereas GAP-43 is a late differentiation marker associated with neurite outgrowth. 16 As shown in Figure 1I , overexpression of p53 alone induced p21, but not GAP-43 ( Figure 1I , lane 2), which might explain why p53 alone cannot induce PC12 cells to differentiate. Upon NGF treatment, endogenous p53 was accumulated accompanied by the induction of p21 and GAP-43 ( Figure 1I, lane 3) . Moreover, the inductions of p21 and GAP-43 by NGF were highly increased upon p53 expression ( Figure 1I , compare lanes 3-4). Taken together, these results implied that p53 plays a role in NGF-mediated differentiation in PC12 cells.
Overexpression of mutant p53 attenuates NGFmediated neurite outgrowth in PC12 cells
To further investigate the role of p53, we generated PC12 cell lines that inducibly express HA-tagged murine p53(A135V) ( Table 1) . This mutant was shown to be dominant negative toward wild-type p53 at the non-permissive temperature (38.51C). 17 Two representative clones, which are capable of expressing comparable amounts of p53(A135V), were chosen for further studies (Figure 2A ). Unlike wild-type p53, p53(A135V) was unable to induce p21 ( Figure 2A ) and growth suppression at the non-permissive temperature ( Figure 2B and C) . Next, we examined the effect of p53(A135V) on neuronal differentiation and found that upon NGF treatment, the neurites were less and shorter in PC12 cells with p53(A135V) expression than that in control cells as the number of cells with neurites was reduced by 59-68% upon p53(A135V) expression ( Figure  2D and E). Likewise, the induction of p21 and GAP-43 by NGF was attenuated or almost completely abolished by p53(A135V) ( Figure 2F ). Similarly, we found that upon treatment with NGF for 6 days, neurite outgrowth was still inhibited by mutant p53(A135V), but the extent of reduction was less profound. Mutant p53 posseses gain-of-function independent of inhibition of wild-type p53, which may be responsible for inhibiting NGF-mediated differentiation. To address this, we generated PC12 cell lines in which endogenous p53 was knocked down (p53KD) ( Table 1) . Two representative clones were presented in Figure 3A . Upon NGF treatment, p53 was accumulated in parental, but not p53KD, PC12 cells ( Figure 3A) . Interestingly, for 3-day treatment with NGF, neurite outgrowth was Human lung carcinoma H1299 cell line that can inducibly express HA-tagged human wild-type p53 under the control of the tetracycline-repressible (Tet-off) promoter p53 is required for neuronal differentiation J Zhang et al markedly reduced by p53 knockdown as cells bearing neurites longer than two-body length decreased from 13 to 0-1.5% ( Figure 3B and C). For 6-day treatment with NGF, the reduction by p53 knockdown became profound as cells bearing neurites longer than two-body length decreased from 56.2 to 11.5-18.8% ( Figure 3B and C). Similarly, we found that NGF induction of p21 and GAP-43 was abolished by p53 knockdown ( Figure 3A ). To confirm whether p53 is required, we generated PC12 cell lines in which endogenous p53 was knocked down and HAtagged wild-type murine p53 is inducibly expressed (Table 1) . Multiple clones were selected, and one representative clone, PC12(p53KD)-HA-p53-28, was shown in Figure 3D . Upon NGF treatment, there was no detectable level of endogenous p53 whereas upon induction, exogenous p53 was expressed ( Figure 3D , both p53 panels). We showed that exogenous p53 or NGF alone was unable to induce neurite outgrowth in p53KD PC12 cells (Figure 3Eb and c). In addition, p21, but not GAP-43, was induced in a p53-dependent manner ( Figure 3D ). However, NGF-mediated neurite outgrowth was rescued by exogenous p53 ( Figure 3E , compare c and e with d and f, respectively) as cells bearing neurites longer than twobody length increased from 2.9 to 10.8% upon 3-day treatment and from 28.1 to 53.2% upon 6-day treatment ( Figure 3F ). Likewise, NGF-mediated induction of GAP-43 was also rescued by exogenous p53 ( Figure 3D , compare lanes 3-4).
p53 is required for NGF-mediated activation of MAPK and its downstream pathway
It is well defined that NGF-mediated neurite outgrowth requires sustained activation of the MAPK pathway, including ERK1/2 18 and Egr-1, a downstream target of the MAPK pathway. 19 This leads us to speculate that the MAPK pathway may not be sufficiently activated in p53KD PC12 cells since they were inert to NGF. We found that upon NGF treatment, phosphorylated ERK1/2 (p-ERK1/2) was accumulated within the first 15 min and maintained for next 30 min, but the extent (Figure 4a ). We would like to note that upon NGF treatment, the level of p53 was increased within 6 h, but not within 30 min (Figure 4a ). Next, we analyzed the activation of MEK1/2, an upstream kinase of ERK1/2, and RSK90, a downstream substrate of ERK1/2. 2 We showed that p-MEK1/2 was detected within 5 min and then slowly decreased to the basal level within 30 min in parental PC12 cells treated with NGF (Figure 4b) . Similarly, p-RSK90 was detected within 5 min, peaked at 10 min, and then decreased to the basal level within 30 min (Figure 4b ). In contrast, MEK1/ 2 and RSK90 was only modestly activated in p53KD PC12 cells (Figure 4b ).
In the above, we showed that NGF-mediated neurite outgrowth was inhibited by p53(A135V). Thus, we examined whether the inhibition is preceded by lack of NGF-mediated activation of the MAPK pathway. We found that p53(A135V) substantially attenuated NGF activation of ERK1/2 ( Figure 4c) . Likewise, NGF induction of Egr-1 was also attenuated by p53(A135V) (Figure 4c ).
To determine whether the MAPK pathway is necessary for p53 to enhance NGF-mediated neurite outgrowth, U0126, a specific MEK1/2 kinase inhibitor, was used. We showed that 
p53 is essential for NGF-mediated differentiation by inducing TrkA
While NGF-mediated activation of MAPK is enhanced by p53, it is also dependent on TrkA. Since NGF initiates its signaling pathway through binding to TrkA, 2 this suggests that p53 modulates TrkA. To test this, the level of phosphorylated TrkA at tyrosine 490 (p-TrkA-Y490), which correlates with activation of the MAPK pathway, 20 was determined. As shown in Figure 5a , NGF elicited an increase of p-TrkA-Y490 within 5 min, which was then decreased to the basal level in parental cells. For quantification purpose, we arbitrarily set the level of p-TrkA-Y490 in parental cells at 1 (Figure 5a ). Interestingly, we found that p53 knockdown markedly decreased the level of p-TrkA-Y490 from 1 to 0.17-0.23 ( Figure 5a ). In addition, upon treatment with NGF, the level of total TrkA protein was slightly increased in parental cells, but much less or no increase in p53KD cells (Figure 5a) . Furthermore, the steady-state level of TrkA in parental cells was notably higher than that in p53KD (Figure 5a ). Again, if we arbitrarily set the level of TrkA in parental cells at 1, the steady-state level of TrkA in p53KD cells is low (0.10-0.14) (Figure 5a ). These results point to a possibility that p53 may regulate the constitutive level of expression of TrkA. To test this, we performed Northern blot analysis and found that p53 knockdown markedly decreased the constitutive level of TrkA ( Figure 5b ). Next, we examined whether exogenous p53 is able to induce TrkA and found that p53 increased the level of TrkA mRNA by1.45-fold in PC12 cells without endogenous p53 and 2.48-fold in those with endogenous p53 (Figure 5c ). We also found that the level of TrkA protein was markedly increased upon induction of exogenous p53 in both parental and p53KD cells (Figure 5d ). Next, we determined whether a physiologically relevant level of p53 is capable of regulating TrkA. To do so, we examined the induction of TrkA by endogenous p53 activated by camptothecin, a DNA-damaging agent, or Nutlin, an inhibitor of Mdm2 that can activate p53 without causing DNA damage, 21 and found that TrkA was induced (Figure 5e ). To rule out the possibility that p53 induction of TrkA is cell-type . SH-SY5Y cells were uninduced or induced to express p53 for 12 h, and then cell lysates were used for Western blot analysis with antibodies against p53, p21, TrkA, and actin. (g) The level of TrkA protein is increased by endogenous p53 activated by DNA damage or Nutlin in SH-SY5Y cells. SH-SY5Y cells were treated with 0.2 nM Nutlin, 0.15 nM campotothecin, 0.25 g/ml doxrubicin for 12 h, and then cell extracts were collected for Western blot analysis with antibodies as described in (f). (h) The level of TrkA protein is increased upon induction of exogenous p53 in H1299 cells. H1299 cells were uninduced or induced to express p53 for 12 h, and then cell lysates were used for Western blot analysis with antibodies against HA, p21, TrkA, and actin. (i) p53 increases NGF-mediated activation of p-TrkA-Y490 and p-ERK1/2. PC12 cells were uninduced or induced to express HA-tagged p53 for 6 h, followed by treatment with NGF for 0, 5, or 15 min. Cell extracts were then collected and analyzed by Western blot analysis with antibodies against HA, total TrkA, p-TrkA-Y490, p-ERK1/2, and actin. (j) Representative microscopy images of PC12 cells mock-treated (Ctrl), treated with Nutlin (Nutlin), NGF (NGF), or both Nutlin and NGF (NGF þ Nutlin) for 3 days p53 is required for neuronal differentiation J Zhang et al specific, we examined the expression of TrkA in human SH-SY5Y neuroblastoma and H1299 lung carcinoma cell lines. SH-SY5Y cells have a low level of TrkA expression and therefore are nonresponsive to NGF. 22, 23 Using the tet-on expression system, we generated SH-SY5Y cell lines that are capable of inducibly expressing HA-tagged wild-type p53 (Table 1) . Two representative clones, SH-SY5Y-7/-9, were used for further studies. H1299-HA-p53-15, which is capable of inducibly expressing HA-tagged wild-type p53 (Table 1) , was also used. We found that TrkA was upregulated by exogenous p53 in SH-SY5Y (Figure 5f ) and in H1299 (Figure 5h ) and by endogenous p53 activated by Nutlin or DNA damage agents in SH-SY5Y (Figure 5g) . Furthermore, to rule out the possibility that p53 acts nonspecifically to elevate levels of other cell surface receptors, we analyzed the expression level of EGFR and found that p53 had no effect.
To determine the functional significance of TrkA induction by p53, we analyzed the level of p-TrkA-Y490 and p-ERK1/2. We showed that upon treatment with NGF, TrkA and ERK1/2 became phosphorylated, which was enhanced by p53 ( Figure 5i ). We would like to note that TrkA and ERK1/2 were not activated by p53 in the absence of NGF although the level of TrkA was increased (Figure 5i, compare lanes 1-2) . Next, we examined the effect of activated endogenous p53 (via induction of TrkA) on NGF-mediated neurite outgrowth in PC12 cells. We found that NGF-mediated neurite outgrowth was markedly enhanced by endogenous p53 activated by Nutlin (Figure 5j ).
TrkA is a direct target gene of p53
To test whether p53 directly induces TrkA, a DNA fragment spanning TrkA promoter from nt À1706 to þ 32 was amplified from the rat genome using PCR. This TrkA promoter and its derivatives, which contain Sp1-like GC-rich elements and/or two potential p53-responsive elements, were then cloned for luciferase assay (Figure 6a ). We showed that the TrkA promoter from nt À1706 to þ 32 led to a 3.5-fold increase of luciferase activity by wild-type p53 but not p53(A135V) whereas the promoter from nt À1033 to þ 32 lost its activity (Figure 6a ). This suggests that the GC-rich elements but not the potential p53-responsive elements are required. As a Figure 6 TrkA is a direct target gene of p53. (a) The TrkA promoter is responsive to wild-type p53. Dual luciferase assay was performed as described in Materials and Methods. The fold increase in relative luciferase activity for each construct was calculated using an empty pcDNA3 vector as a control. (b) The GC-rich elements are responsible for p53 activation of the TrkA promoter. Constructs that contain point mutations in the GC-rich elements or a deletion of the GC-rich elements were generated as described in Materials and Methods. (c) p53 binds to the GC-rich elements in the TrkA promoter. Gel shift analysis was performed with a 176-bp DNA fragment containing the GC-rich elements in the TrkA promoter. The p53-DNA complex was resolved in 4% polyacrylamide gel. For competition assays, unlabeled wild-type RGC (20 and 100 ng) or mutant RGC (20 and 100 ng) were added to the reaction run in lanes 3-4 and 5-6, respectively. For 'supershifting' the p53-DNA complex, 1 mg of antip53 monoclonal antibody Pab1801 was added in the reaction run in lane 7. (d-e) Wild-type p53 (d) but not mutant p53 (e), binds to the TrkA and p21 promoters in vivo. ChIP assays were performed as described in Materials and Methods. Anti-HA antibody was used to immunoprecipitate p53-DNA complexes. Anti-Flag antibody was used as a control. (f) The TrkA promoter is bound by endogenous p53 at a nonstressed condition. ChIP assays were performed as described in Materials and Methods. Rabbit anti-p53 antibody was used to immunoprecipitate p53-DNA complexes. Rabbit IgG was used as a control p53 is required for neuronal differentiation J Zhang et al control, the p21 promoter led to 2.5-fold increase of luciferase activity by wild-type p53 (Figure 6a ). Previously, GC-rich elements were shown to be responsive to p53. 24 To test this, we made point mutations or a deletion in the GC-rich elements and found that the deletion or point mutations led to complete or partial inactivation of the TrkA promoter (Figure 6b) .
To demonstrate that p53 directly binds to the GC-rich elements, we performed DNA gel shift assay with 32 P-labeled 176-bp DNA fragment spanning the region of the GC-rich elements in the TrkA promoter (Figure 6c) . We found that when the recombinant p53 protein was mixed with the DNA fragment, a complex was detected, presumably containing both p53 and the 32 P-labeled DNA, which was not detected in the absence of p53 protein. Moreover, we showed that the level of the p53-DNA complex was reduced in a dosagedependent manner by an excess amount of unlabeled DNA fragment containing a p53-binding site from the ribosomal gene cluster (Wt-RGC) but not the one containing a mutant p53-binding site (Mt-RGC). Furthermore, we showed that upon addition of anti-p53 to the mixture of p53 and DNA, the complex was 'supershifted. ' To further demonstrate the involvement of the GC-rich elements, chromatin immunoprecipitaion (ChIP) was performed with primers to amplify a fragment in the TrkA and p21 promoters. Anti-HA was used to bring down p53-DNA complexes. Anti-Flag antibody was used as a control. We showed that the fragment containing the GC-rich elements was enriched in anti-HA (i.e. p53 containing), but not in antiFlag, immunocomplexes (Figure 6d) . Similarly, the p21 promoter was immunoprecipitated with p53 ( Figure 6d ). We also showed that p53(A135V) was unable to bind to the TrkA or p21 promoter (Figure 6e) . Furthermore, we found that at the nonstressed condition, the TrkA promoter was bound by endogenous p53 whereas little p53 bound to the p21 promoter (Figure 6f) , consistent with the above observation that the basal level of p53 is necessary for the constitutive level of TrkA expression.
Discussion
In this study, we provided evidence that p53 is required for NGF-mediated neuronal differentiation in PC12 cells. We found that p53 is required for NGF-mediated activation of the MAPK pathway. Most importantly, we found that the constitutive level of endogenous p53 is necessary for sustained expression of the constitutive level of TrkA. In addition, when activated by NGF or other stimuli, p53 is able to further induce the expression of TrkA. Moreover, induction of TrkA by activated endogenous wild-type p53 enhances neurite outgrowth mediated by NGF. Interestingly, p53 alone is not sufficient to activate the signaling pathways of TrkA and MAPK. Taken together, our data indicate that when PC12 cells with endogenous p53 are exposed to NGF, p53 is activated and then directly induces the expression of TrkA, which in turn provides more binding partners for NGF, amplifying the level of activation of TrkA and subsequently, the signaling pathway for neuronal differentiation. However, in PC12 cells wherein endogenous p53 is knocked down or inhibited by mutant p53, the constitutive level of expression of TrkA is substantially reduced. In addition, the amplifying cycle of the activation of TrkA by NGF via p53 is broken down. As a result, upon exposure to NGF, the signaling pathway leading to neuronal differentiation may be weakly activated, but is not strong enough to elicit neurite outgrowth. It should be noted that the extent of attenuation in neurite outgorwth by p53(A135V) is less than that by p53 knockdown, especially during a extended treatment (6 days) with NGF. One possibility is that p53(A135V) may posses some activity since it is a temperature-sensitive mutant. 17 The other possibility is that when both mutant and wild-type p53 are expressed in the same cell, there is always a fraction of active wild-type p53 homotetramer (up to 25%). This may explain why mutant p53 cannot totally, and in some case, may not be able to, inhibit NGF-mediated neurite outgrowth. 13 Our data are consistent with earlier reports that reconstituted TrkA can restore the response to NGF for PC12 cells deficient in TrkA 25 and overexpression of TrkA can further accelerate NGF-mediated neuronal differentiation. 26 Based on these findings, a model for the role of p53 in neuronal differentiation is presented in Figure 7 .
It is well known that upon NGF treatment, neuronal cells are permanently arrested and undergo neurite outgrowth. Thus, cell cycle arrest and neurite outgrowth are two critical events for neuronal differentiation. 2 Our results indicated that p53 regulates both events through induction of p21 and GAP-43. We showed that p53 knockdown and p53(A135V) impair NGF-mediated induction of p21 whereas reconstituted p53 in p53KD PC12 cells restores it. These results are consistent with a previous report that p53 plays a role in NGF-mediated differentiation by inducing cell cycle arrest. 13 Interestingly, although p53 alone induces p21 expression, this induction is not sufficient to promote neurite outgrowth in the absence of NGF, suggesting that other NGF-mediated activities are also required. Unlike the induction of p21, p53 alone is not sufficient, but required for, NGF to induce GAP-43. Since Figure 7 A model of p53 for neurite outgrowth in PC12 cells p53 is required for neuronal differentiation J Zhang et al the increased expression of GAP-43 by NGF is due to stabilization of GAP-43 mRNA, 27 it is likely that p53 may modulate the expression of GAP-43 indirectly by regulating other neuronal differentiation-related genes, including TrkA.
TrkA is shown to be required for cell survival during differentiation and for cell death during neurotrophin deficiency. 28, 29 Thus, p53 induction of TrkA may impinge on other pathways. Indeed, a recent study showed that apoptosis induced by TrkA in neuroblastoma is p53 dependent. 30 This may explain why the level of TrkA, which correlates with spontaneous regression of neuroblastoma, is scored as a favorable prognosis marker. 31 On the other hand, considering the fact that TrkA is crucial for the development of sympathetic neuron, 32 one may argue how p53-null mice, which are deficient in p53 and consequently, may be low in TrkA, develop normally. 33 This does not necessarily contradict the observations in this study. Upon further examination, a small, but detectable number of p53-null mice have defects in neural tube closure, especially in female embryos. 9, 34 In addition, p53 is not the only regulator of TrkA. We showed that p53 knockdown leads to B30-40% reduction of the constitutive level of TrkA. Thus, a 'backup' gene, such as other p53 family members that are capable of inducing some p53 target genes, 4 may compensate for the loss of TrkA expression in the absence of p53.
Materials and Methods
Materials
PC12 Tet-off cells, which are capable of expressing Tet-VP16 for the tetracycline-repressible expression system, were purchased from Clontech (cat. No. 630906). SH-SY5Y cell line (cat #CRL-2266) was purchased from ATCC. The dual-luciferase assay kit and NGF (murine, 2.5 s) were purchased from Promega. Antibodies against p21, Egr-1, and TrkA were purchased from Santa Cruz Biotechnology. Anti-HA antibody was purchased from Covance. Anti-p-TrkA-Y490, anti-p-ERK1/2, antip-MEK1/2, anti-p-RSK90, and MEK1/2 kinase inhibitor U0126 were purchased from Cell Signaling. Anti-actin and anti-GAP-43 were purchased from Sigma. Anti-ERK1 was purchased from BD Biosciences.
Plasmids and mutagenesis
To generate constructs for the tetracycline-repressible (tet-off) expression system, HA-tagged wild-type and mutant murine p53 were cloned into a tetracycline-repressible expression vector, pUHD 10-3, at its EcoRI site. To generate constructs for the tetracycline-inducible (tet-on) expression system, HA-tagged wild-type human p53 was cloned into a tetracyclineinducible expression vector, pcDNA4, at its EcoRI site (pcDNA4-HA-p53). To generate constructs for luciferase assay, wild-type and mutant murine p53 were cloned into pcDNA3. To generate constructs expressing small interference RNAs (siRNAs) targeting the rat p53 coding region, a region of 19 nucleotides in the rat p53 gene (GAG CAT TGC CCG GAG CTG C or GACTCC AGT GGG AAT CTT C) was selected for synthesis, which were then cloned into a puromycin-selectable siRNA expression vector under the control of the U6 promoter (pBabe-U6) and the resulting plasmid was designated as pBabe-U6-si-p53. To generate the luciferase reporter under the control of the TrkA promoter (pGL2/-1706 TrkA), a 1738-bp DNA fragment containing the TrkA promoter was amplified from genomic DNA purified from PC12 cells using a upstream primer, 5 0 -CTG CAG AAC TCA CGC CCT GTA ATG-3 0 , and a downstream primer, 5 0 -AAG CTT GCT TGG CTG CTG TAG GA-3 0 . The DNA fragment was confirmed by sequencing and then cloned into pGL2-basic vector at SmaI and HindIII sites to generate the pGL2/-1706 TrkA vector. To generate the luciferase reporter, pGL2/-1302 TrkA, a SacI-HindIII fragment obtained from the pGL2/-1706 TrkA was cloned into pGL2-Basic. To generate the luciferase reporter, pGL2/-1033 TrkA, an XhoI-HindIII fragment from the pGL2/-1302 TrkA was cloned into pGL2-Basic. To generat the luciferase reporter, pGL2/-774 TrkA, a BglII-HindIII fragment from the pGL2/-1033 TrkA vector was cloned into pGL2-Basic. Constructs containing either point mutations or deletion in the TrkA promoter were generated using PCRbased mutagenesis and confirmed by sequencing. Briefly, two PCR reactions were performed using pGL2/-1706 TrkA as a template: one with an upstream primer P1 (5 0 -cct cct ggg ctt tca gac ttc t-3 0 ) and a specific downstream primer (see below for details); and other with a specific upstream primer (see below for details) and a downstream primer P2 (5 0 -cct cag ttg aca ggc taa ata-3 0 ). Next, these two PCR products were mixed and used as a template for the third PCR reaction using primers P1 and P2. The PCR products were then used to replace the corresponding region in the TrkA promoter at the RsrII and SacII sites. Specifically, to generate the TrkA promoter with point mutations in the GC-rich elements, the specific downstream primer was P3 (5 0 -ttg aca ggc taa ata ttt tcc ctt gac ttg gtg gga ggg gcg gag aga aca gag aagt-3 0 ) whereas the specific upstream primer was P4 (5 0 -GCT TAG GCC CTT TCC AGA AAC AGA TTG GTT TAC GCC ACC GAC TTC TCT GTT CTC TCt atc CC-3 0 ). To generate the TrkA promoter with deletion of the GC-rich elements, the specific downstream primer was P5 (5 0 -CTG GTG GGA GAG TGG GGC-3 0 ) whereas the specific upstream primer was P6 (5 0 -gcc cca ctc tcc cac cag-3 0 ).
Cell culture
The PC12 tet-off cells were maintained in Ham's F12 medium supplemented with 15% horse serum and 2.5% fetal bovine serum (FBS) as suggested by ATCC. SH-SY5Y tet-on cells were cultured in 1 : 1 mixture of Eagle's medium and Ham's F12 medium with 10% tetracycline approved FBS as suggested by ATCC. H1299 tet-off cells were cultured in DMEM with 10% FBS. Selection drugs were added to the medium as needed. Cells were grown at 371C with 5% CO 2 whereas mutant p53 inducible PC12 cells were cultured at 38.51C. All inductions were performed in culture medium with either 10% tet-system-approved serum (for tet-off system) or 10% regular FBS plus 2 mg/ml tetracycline (for tet-on system). For NGF treatment, cells were uninduced or induced to express protein of interest and then switched to a medium containing 2% tetracycline-approved FBS plus NGF. For treatment with both NGF and U0126, cells were pretreated with 10 mM of U0126 for 2 h before adding NGF. The concentration of NGF used for all the experiments was 100 ng/ ml if not specified.
Establishment of stable cell lines
All transfections were achieved using Lipofectamine 2000 according to the manufacturer's instructions (Invitrogen). For generation of wild-type or mutant p53-inducible cell lines, parental PC12 tet-off cells were cotransfected with a pUHD10-3 vector, which expresses either wild-type or mutant p53, and pBabe vector, which expresses the puromycin-resistant gene for clone selection. Cells were selected with 1 mg/ml of puromycin and 100 mg/ml of G418 for 4 weeks. Individual clones were screened for inducible expression of p53 by Western blot analysis. For generation of p53KD PC12 cell lines, PC12 cells were transfected with pBabe-U6-si-p53
and selected with puromycin for 4 weeks. Individual clones were screened for lack of accumulation of endogenous p53 upon NGF treatment by Western blot analysis. For generation of PC12 cell lines in which endogenous rat p53 is knocked down and an exogenous murine p53 is inducibly expressed, pBabe-U6-si-p53 and pUHD10-3 vector-expressing wild-type murine p53 were co-transfected into PC12 cells. After transfection, cells were selected with 1 mg/ml of puromycin and 100 mg/ ml of G418 for 4 weeks. Individual clones were screened for inducible expression of p53 or lack of accumulation of endogenous p53 upon NGF treatment by Western blot analysis. To generate SH-SY5Y tetracyclineinducible (tet-on) cell lines, SH-SY5Y cells were transfected with pcDNA6 (Invitrogen), which encodes a tetracycline repressor, and selected with 7.5 mg/ml of blasticidine for 8 weeks. Multiple clones that can express the tetracycline repressor were selected and used for subsequent transfection with pcDNA4-HA-p53 plasmid. After selection with 100 mg/ml of zeocin for 8 weeks, individual clones were screened for inducible expression of p53 by Western blot analysis.
Growth rate analysis
To determine the rate of cell growth, 5 Â 10 4 PC12 cells were seeded per 60-mm diameter plate. Cells were uninduced or induced to express the protein of interest in the presence or absence of tetracycline (2 mg/ml). Culture media were replaced every 72 h. Each day over a 5-day period, three plates for each group were rinsed twice with PBS to remove dead cells. Live cells on the plates were trypsinized and samples from each plate were counted three times using a Coulter cell counter (Coulter Corporation, Miami, FL, USA). The average number of cells from each group was used for growth rate determination.
DNA histogram analysis
Cells were seeded at 2 Â 10 5 per 90-mm-diameter plate and uninduced or induced to express p53 in the presence or absence of tetracycline (2 mg/ ml). At 72 h after induction, both floating and dead cells in the media and live cells on the plate were collected and fixed with 10 ml of 75% ethanol overnight and then centrifuged and resuspended in 300 ml of PBS solution containing 50 mg/ml each of RNase A (Sigma) and propidium iodide (Sigma). The stained cells were analyzed in a fluorescence-activated cell sorter (FACS Calibur; Becton Dickinson) within 4 h. The percentage of cells in the sub-G1, G1, S, and G2/M phases was determined by the Cell Quest program.
Neurite outgrowth assay
Cells (5 Â 10 4 ) were plated in each well of the six-well plate. Cells were uninduced or induced as needed. After induction, culture medium was changed to a differentiation medium (2% tet-system-approved FBS and 100 ng/ml NGF) and replaced every 2 days. Cells with at least one neurite longer than two-body length were counted as neurite positive. At least 500 cells were counted for each group performed in triplicate.
Western blot analysis
Cells were washed and collected from plates in PBS solution, resuspended with 2 Â sample buffer, and boiled for 5 min. Proteins were then resolved in an 8% SDS-PAGE gel and transferred to a nitrocellulose membrane.
RNA isolation and Northern blot analysis
Total RNA was isolated using Trizol reagent (Invitrogen) and used for Northern blot analysis. The TrkA probe was made from a 650-bp cDNA fragment amplified by RT-PCR with an upstream primer (5 0 -ATG AGA CCA GCT TCA TC-3 0 ) and a downstream primer (5 0 -GCT CCC ACTT GAG AAT G-3 0 ). The glyceraldehyde-3-phosphate dehydrogenase probe was made as described. 35 
Luciferase assay
The dual-luciferase assay was carried out as previously reported. 35 A luciferase reporter (300 ng) along with pcDNA3 or pcDNA3 that expresses wild-type or mutant p53 (300 ng) was transfected into PC12 cells plated in a 24-well plate. All experiments were performed in triplicate.
Gel-shift assay
The assay was carried out as described. 36 Specifically, a 176-bp fragment containing the GC-rich elements was amplified by PCR using pGL2/-1706 TrkA as template with 5 0 primer, TrkA-RE-5 (5 0 -CTC CTG GGC TTT CAG ACT TC-3 0 ), and 3 0 primer, TrkA-RE-3 (5 0 -CCC TAG TTG ACA GGC TAA ATA-3 0 ). The fragment was labeled with 32 P. Approximately 1 ng of the labeled probe DNA and 20 ng p53 protein were added to a mixture of 20 mM HEPES, pH 7.9, 25 mM KCl, 0.1 mM EDTA, 10% glycerol, 2 mM MgCl 2 , 2 mM spermidine, 0.5 mM DTT, 0.025% NP-40, 100 ng doublestraded poly(dG:dC), and 2 mg BSA. The p53 protein was expressed in a baculovirus expression system and affinity purified using anti-p53 monoclonal antibody PAb421. The p53-responsive element in the ribosomal gene cluster (RGC) was used as a competitor. 37 The wildtype and mutant RGC-containing double-stranded oligonucleotides for competition were as described. 38 
ChIP assay
ChIP was performed as described. 35 The primers used to detect the TrkA promoter were: TrkA-RE-5 (5 0 -CTC CTG GGC TTT CAG ACT TC-3 0 ) and TrkA-RE-3 (5 0 -CCC TAG TTG ACA GGC TAA ATA-3 0 ). The primers used to detect the p21 promoter were: p21-RE-5 (5 0 -Gcc tcc tga gtg ctg gg-3 0 ) and p21-RE-3 (5 0 -AGG GTG GGG GGT GGT AT-3 0 ).
